Abstract:In our continuing efforts to develop novel c-Met inhibitors as potential anticancer candidates, a series of new N-sulfonylamidine derivatives were designed, synthesized via Cu-catalyzed multicomponent reaction (MCR) as the key step, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231). Most of the target compounds showed moderate to significant potency at both the enzyme-based and cell-based assay and possessed selectivity for A549 and HT-29 cancer cell lines. The preliminary SAR studies demonstrated that compound 26af (c-Met IC50 = 2.89 nM) was the most promising compound compared with the positive foretinib, which exhibited the remarkable antiproliferative activities, with IC50 values ranging from 0.28 to 0.72 μM. Mechanistic studies of 26af showed the anticancer activity was closely related to the blocking phosphorylation of c-Met, leading to cell cycle arresting at G2/M phase and apoptosis of A549 cells by a concentration-dependent manner. The promising compound 26af was further identified as a relatively selective inhibitor of c-Met kinase, which also possessed an acceptable safety profile and favorable pharmacokinetic properties in BALB/c mouse. The favorable drug-likeness of 26af suggested that N-sulfonylamidines may be used as a promising scaffold for antitumor drug development. Additionally, the docking study and molecular dynamics simulations of 26af revealed a common mode of interaction with the binding site of c-Met. These positive results indicated that compound 26af is a potential anti-cancer candidate for clinical trials, and deserves further development as a selective c-Met inhibitor.

Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors

Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Design, Synthesis and Biological Evaluation of Novel α‐Acyloxycarboxamide‐Based Derivatives as c‐Met Inhibitors

Design, Synthesis and Biological Evaluation of Novel 4-Phenoxypyridine Based 3-Oxo-3,4-dihydroquinoxaline-2-carboxamide Derivatives As Potential C-Met Kinase Inhibitors.

Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

Design, Synthesis and Biological Evaluation of Novel 4-Phenoxypyridine Derivatives Containing Semicarbazones Moiety As Potential C-Met Kinase Inhibitors.

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors

Design, synthesis and biological evaluation of novel <i>N</i>-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

Design, Synthesis and Biological Evaluation of Novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide Derivatives As Potential C-Met Kinase Inhibitors

Discovering Potent Inhibitors Against C-Met Kinase: Molecular Design, Organic Synthesis and Bioassay

Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors

Discovery of Imidazopyridine Derivatives As Novel C-Met Kinase Inhibitors: Synthesis, SAR Study, and Biological Activity

Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors

Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.

Structure-based Discovery of Novel 4-(2-fluorophenoxy)quinoline Derivatives As C-Met Inhibitors Using Isocyanide-Involved Multicomponent Reactions.

Design, Synthesis and Biological Evaluation of 4-Phenoxy- Pyridine/Pyrimidine Derivatives as Dual VEGFR-2/c-Met Inhibitors

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors

Design, Synthesis and Biological Evaluation of Sulfonylamidines As Potent C-Met Inhibitors by Enhancing Hydrophobic Interaction.

Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (C-Met) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(quinolin-6-ylmethyl)-1h-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1h-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment Of

Identification and Synthesis of N′-(2-oxoindolin-3-ylidene)hydrazide Derivatives Against C-Met Kinase

Structure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy